How Artificial Intelligence Can Enhance Epilepsy Management

By Staff Writer

February 13, 2024

Introduction

The application of artificial intelligence (AI) in healthcare is increasingly becoming a topic of interest, especially to detect diseases from pathology samples or imaging. In recognition of World Epilepsy Week, we take a look at 4 studies on developments made in AI use in epilepsy research and innovation, discussing how these may lead to improved outcomes for those living with one of the most common neurological disorders.

AI and Epilepsy Detection

The first study by Jin et al. discusses the use of machine learning in detecting Focal Cortical Dysplasia (FCD), a major cause of pharmacoresistant epilepsy in those undergoing surgical resection. The use of magnetic resonance imaging (MRI) is mostly used to detect these features, however, some FCD type II lesions are too subtle to be detected by conventional MRI scans. Finding a previously undiscovered lesion may change the surgical technique and improve seizure results. Using surface-based MRI morphometry coupled with machine learning, they were able to detect FCD with a sensitivity of 73.7% and specificity of 90.0% in this study. This method showed robust performance across different centres and scanners, suggesting AI’s potential as a valuable tool in presurgical evaluations for patients with pharmacoresistant epilepsy.

AI in Classifying Temporal Lobe Epilepsy

The second study explored in depth the use of AI in classifying Temporal Lobe Epilepsy (TLE). Gleichgerrcht et al. used support vector machine (SV) and deep learning (DL) models based on region of interest (ROI-based) structural and diffusion brain MRI data. The models showed better or similar (68–75%) performance in identifying TLE compared to lateralizing the side of TLE. The models performed more accurately for patients with hippocampal sclerosis (68–76%) than non-lesional patients (53–62%). Overall, the study demonstrated the potential of machine learning and AI in future epilepsy care, especially in TLE.

AI for Epileptic Seizure Prediction

The third study, Daoud and Bayoumi examined the use of deep learning in predicting epileptic seizures. Patients who suffer from epilepsy will experience a significant impact on their lives if they are able to anticipate the onset of seizures.The researchers developed a patient-specific seizure prediction technique based on deep learning and applied to long term scalp electroencephalogram (EEG). Four deep learning models were suggested as a method to improve classification accuracy and prediction time by extracting the most discriminative characteristics. The suggested method uses the convolutional neural network (CNN) to extract significant spatial data to predict seizures earlier than current methods. This approach yielded a high accuracy of 99.6% and a very early seizure prediction time, making it one of the most efficient methods for seizure prediction.

AI for Intracranial Interictal Epileptiform Discharges Detection

In the final study Quon and colleagues explored the use of deep learning in classifying intracranial interictal epileptiform discharges (IEDs). Epileptiform discharges that occur between seizures are known as IEDs and is also used in differentiating epilepsy types. Previous research has linked IEDs to memory loss, increased seizure frequency and recurrence, making IEDs clinically relevant. Human visual annotation of IEDs is the gold standard, however it takes time and training to classify EEG patterns correctly. The researchers developed an automated method, “AiED,” which combined a template-matching algorithm and a CNN. The method achieved comparable performance to human reviewers, suggesting its potential in supporting clinical and research EEG analyses by reducing time and resources spent.

Concluding remarks:

In conclusion these studies demonstrate the potential of AI in improving the detection and management of epilepsy. This will lead to improved accuracy, lower capacity demand on healthcare services and overall better outcome for patients living with epilepsy. As AI technology continues to evolve, its application in epilepsy management is likely to become even more significant.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.